Search bioRxiv⌕ Search

Biology subjects

Dowlati, A.

Publications and source records attributed to Dowlati, A..

2 recordsLinked to original sources

Basal cell of origin resolves neuroendocrine-tuft lineage plasticity in cancer

Summary paragraphNeuroendocrine and tuft cells are rare, chemosensory epithelial lineages defined by expression of ASCL1 and POU2F3 transcription factors, respectively1,2. Neuroendocrine cancers, including small cell lung cancer (SCLC), frequently display tuft-like subsets, a feature linked to poor patient outcomes3-13. The mechanisms driving neuroendocrine-tuft tumour heterogeneity, and the origins of tuft-like cancers are unknown. Using multiple genetically-engineered animal models of SCLC, we demonstrate that a basal cell of origin (but not the accepted neuroendocrine origin) generates neuroendocrine-tuft-like tumours that highly recapitulate human SCLC. Single-cell clonal analyses of basal-derived SCLC further uncovers unexpected transcriptional states and lineage trajectories underlying neuroendocrine-tuft plasticity. Uniquely in basal cells, introduction of genetic alterations enriched in human tuft-like SCLC, including high MYC, PTEN loss, and ASCL1 suppression, cooperate to promote tuft-like tumours. Transcriptomics of 944 human SCLCs reveal a basal-like subset and a tuft-ionocyte-like state that altogether demonstrate remarkable conservation between cancer states and normal basal cell injury response mechanisms14-18. Together, these data suggest that the basal cell is a plausible origin for SCLC and other neuroendocrine-tuft cancers that can explain neuroendocrine-tuft heterogeneity--offering new insights for targeting lineage plasticity.

cancer biology↗

Genomic analyses of high-grade neuroendocrine gynecological malignancies reveal a unique mutational landscape and therapeutic vulnerabilities

The high-grade neuroendocrine carcinoma of gynecologic origin (NEC-GYN) is a highly aggressive cancer affecting young women. The clinical management of NEC-GYN is often extrapolated from their counterpart, small cell carcinoma of the lung (SCLC), but, unfortunately, they have limited effect. In our NEC-GYN cohort, median progression-free survival (PFS) and overall survival (OS) were 1 and 12 months, respectively, indicating their highly lethal nature. Our comprehensive genomic analyses unveiled that NEC-GYN harbors a higher mutational burden with distinct mutational landscapes from SCLC. We identified 14 cancer driver genes (FDR <0.01) including the most frequently altered KMT2C (100%), KNL1 (100%), NCOR2 (100%), and CCDC6 (93%) genes. Transcriptomic analyses identified several novel gene fusions in NEC-GYN. Furthermore, NEC-GYN exhibited a highly immunosuppressive state and uniquely belonged to the YAP1 high molecular subtype that promotes multidrug resistance. Our study suggests an urgent need to reevaluate the therapeutic options and targets for NEC-GYN.

genomics↗